Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas

NCT03805022 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT03805022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03805022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas
Lead sponsor
Institut Bergonié
Phase
Phase 3
Overall status
Recruiting
Start date
February 14, 2019
Completion date
December 31, 2028
Enrollment
351 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic soft-tissue sarcoma, resectable